Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Non-Current Liabilities (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Total Non-Current Liabilities data on record, last reported at $10.4 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 8.02% year-over-year to $10.4 million; the TTM value through Sep 2025 reached $10.4 million, down 8.02%, while the annual FY2024 figure was $2.5 million, 93.47% down from the prior year.
  • Total Non-Current Liabilities reached $10.4 million in Q3 2025 per STOK's latest filing, down from $10.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $53.1 million in Q1 2022 and bottomed at $2.5 million in Q4 2024.
  • Average Total Non-Current Liabilities over 4 years is $29.7 million, with a median of $36.4 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: dropped 4.69% in 2023, then tumbled 93.47% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $39.8 million in 2022, then decreased by 4.69% to $38.0 million in 2023, then crashed by 93.47% to $2.5 million in 2024, then soared by 320.98% to $10.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $10.4 million in Q3 2025, $10.9 million in Q2 2025, and $12.1 million in Q1 2025.